肺塞栓症の世界市場レポート 2025年

肺塞栓症市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.5％で36億3,000万米ドルに成長します。予測期間の成長は、標的療法、遠隔医療と遠隔モニタリング、健康公平性への取り組み、世界ヘルスへの取り組みに起因しています。予測期間の主な動向には、診断における人工知能、新規抗凝固薬、肺塞栓症対応チーム、患者中心のケアなどがあります。

血栓の急増は、近い将来肺塞栓症市場の成長の原動力になると予測されています。血栓は医学的には血栓と呼ばれ、血管内でゲル状または半固体の塊として現れます。血栓の存在は、肺への血液の自然な流れを妨げ、閉塞を引き起こすことにより、肺塞栓症のリスクを高める。このような血栓は、一般的に足の深部静脈で観察され、肺塞栓症の可能性を著しく高めます。例として、2022年4月のGavi（ワクチン同盟）の論文では、COVID-19曝露後30日以内に、生命を脅かす肺血栓の発生が33倍、深部静脈血栓症のリスクが5倍に急増する可能性が報告されています。その結果、血栓の有病率の上昇は肺塞栓症市場の成長にとって重要な促進要因となっています。

がんの有病率の増加が肺塞栓症市場の成長を牽引すると予想されます。がんは、体内の細胞の制御不能な異常増殖によって特徴づけられる疾患群を指します。がんの罹患率の増加は、がん患者の肺塞栓症のような血栓のリスクを増加させ、特殊な薬剤を含む診断および治療に対する需要の増加につながります。例えば、2024年1月、米国の非営利団体である米国がん協会は、がん患者数が2023年の1,958,310人から2024年には2,001,140人に増加し、2.19％の増加を反映していると報告しました。その結果、がんの有病率の増加が肺塞栓症市場の拡大を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界肺塞栓症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の肺塞栓症市場：成長率分析
• 世界の肺塞栓症市場の実績：規模と成長, 2019-2024
• 世界の肺塞栓症市場の予測：規模と成長, 2024-2029, 2034F
• 世界肺塞栓症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肺塞栓症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品
• 機械装置
• その他の治療法
• 世界の肺塞栓症市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胸部X線
• 心電図（ECG）
• 磁気共鳴画像（MRI）
• コンピュータ断層撮影スキャン
• 肺血管造影検査
• 静脈造影検査
• 静脈超音波検査
• Dダイマー検査
• その他の診断
• 世界の肺塞栓症市場症状別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 息切れ
• 胸痛
• 咳
• 不整脈
• めまい
• 熱
• チアノーゼ
• その他の症状
• 世界の肺塞栓症市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の肺塞栓症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の肺塞栓症市場、医薬品の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗凝固剤
• 血栓溶解剤
• 世界の肺塞栓症市場、機械装置のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 下大静脈（IVC）フィルター
• カテーテル補助血栓除去術
• 世界の肺塞栓症市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外科的塞栓除去術
• 支持療法

第7章 地域別・国別分析

• 世界の肺塞栓症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の肺塞栓症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肺塞栓症市場：競合情勢
• 肺塞栓症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co.Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi S.A.
• Bristol Myers Squibb Company
• GSK plc
• Abbott Laboratories
• AstraZeneca plc
• Medtronic plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Mylan N.V.
• Daiichi Sankyo Co. Ltd.
• Boehringer Ingelheim International GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肺塞栓症市場2029：新たな機会を提供する国
• 肺塞栓症市場2029：新たな機会を提供するセグメント
• 肺塞栓症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A pulmonary embolism is a condition characterized by the blockage of the pulmonary artery, which carries blood from the heart to the lungs. This blockage typically results from a blood clot that has traveled from another part of the body, most commonly the legs. Symptoms of a pulmonary embolism can vary, ranging from sudden shortness of breath to chest pain, coughing up blood or bloody mucus, and other signs, with the severity depending on the size and location of the clot.

The primary types of treatment for pulmonary embolism encompass medications, mechanical devices, surgery, and other therapeutic interventions. Medications are substances used for medical purposes to treat, manage, prevent, or alleviate various medical conditions and illnesses. Diagnosis of a pulmonary embolism involves various methods, including chest X-rays, electrocardiograms (ECGs), magnetic resonance imaging (MRI), computed tomography scans, pulmonary angiography, venography, venous ultrasound, D-Dimer tests, and others. Symptoms may include shortness of breath, chest pain, cough, irregular heartbeat, dizziness, fever, cyanosis, and more. Medications for treating pulmonary embolism are primarily distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other relevant channels. Healthcare providers in hospitals, specialty clinics, homecare settings, and other medical facilities typically manage the treatment of pulmonary embolism.

The pulmonary embolism market research report is one of a series of new reports from The Business Research Company that provides pulmonary embolism market statistics, including pulmonary embolism industry global market size, regional shares, competitors with a pulmonary embolism market share, detailed pulmonary embolism market segments, market trends and opportunities and any further data you may need to thrive in the pulmonary embolism industry. This pulmonary embolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pulmonary embolism market size has grown rapidly in recent years. It will grow from $2.03 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to anticoagulant therapies, research and clinical trials, pulmonary embolism awareness, vte prophylaxis.

The pulmonary embolism market size is expected to see rapid growth in the next few years. It will grow to $3.63 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to targeted therapies, telemedicine and remote monitoring, health equity initiatives, global health initiatives. Major trends in the forecast period include artificial intelligence in diagnosis, novel anticoagulants, pulmonary embolism response teams, patient-centered care.

The burgeoning prevalence of blood clots is anticipated to be a driving force behind the growth of the pulmonary embolism market in the foreseeable future. Blood clots, medically referred to as thrombi, manifest as gel-like or semi-solid masses within blood vessels. The presence of blood clots escalates the risk of pulmonary embolism by impeding the natural flow of blood to the lungs, causing a blockage. These clots are typically observed in the deep veins of the legs, significantly increasing the likelihood of pulmonary embolism. As an illustration, a Gavi, the Vaccine Alliance article from April 2022 reported a thirty-three-fold surge in the potential occurrence of life-threatening lung clots and a five-fold increase in deep vein thrombosis risk within thirty days after COVID-19 exposure. Consequently, the escalating prevalence of blood clots is a key driver for the growth of the pulmonary embolism market.

The growing prevalence of cancer is expected to drive the growth of the pulmonary embolism market. Cancer refers to a group of diseases marked by the uncontrolled and abnormal growth of cells in the body. The rising incidence of cancer increases the risk of blood clots, such as pulmonary embolism, among cancer patients, leading to higher demand for diagnostics and treatments, including specialized medications. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization, reported that the number of cancer cases rose to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting an increase of 2.19%. As a result, the increasing prevalence of cancer is driving the expansion of the pulmonary embolism market.

Prominent companies operating in the pulmonary embolism market are dedicated to introducing cutting-edge products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter to maintain a competitive edge. As of June 2023, Inari Medical Inc., a US-based medical device company, has launched the Triever16 Curve catheter and the RevCore thrombectomy catheter. The innovative Triever16 Curve catheter is specially designed for peripheral thrombectomy and pulmonary embolism procedures. Its high trackability and pre-shaped curve facilitate focused aspiration. Moreover, the catheter's unique design offers easy access to larger and more powerful 20F or 24F catheters. On the other hand, the RevCore thrombectomy catheter has been developed for the treatment of venous in-stent thrombosis. This mechanical thrombectomy device utilizes a nitinol basket for capturing and removing blood clots, enhancing the safety and efficacy of pulmonary embolism procedures.

In February 2022, Boston Scientific International, a U.S.-based medical device company, acquired Baylis Medical Company Inc. for $1.75 billion. This acquisition strengthens Boston Scientific's portfolio by enhancing its offerings in structural heart disease and electrophysiology, including advanced transseptal access solutions. Baylis Medical Company Inc., a Canada-based medical device company, specializes in pulmonary embolism interventional tools.

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pulmonary embolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The pulmonary embolism market consists of revenues earned by entities by providing services such as medical management, thrombolytic therapy, monitoring and oxygen therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pulmonary embolism market also includes sales of diagnostic imaging equipment, oxygen delivery devices, interventional devices, medical alert systems and pulse oximeters. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pulmonary Embolism Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pulmonary embolism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pulmonary embolism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pulmonary embolism market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medications; Mechanical Devices; Other Treatments
• 2) By Diagnosis: Chest X-Ray; Electrocardiogram (ECG); Magnetic Resonance Imaging (MRI); Computed Tomography Scan; Pulmonary Angiography; Venography; Venous Ultrasound; D-Dimer Test; Other Diagnosis
• 3) By Symptoms: Shortness Of Breath; Chest Pain; Cough; Irregular Heartbeat; Dizziness; Fever; Cyanosis; Other Symptoms
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Medications: Anticoagulants; Thrombolytics
• 2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters; Catheter-Assisted Thrombectomy
• 3) By Other Treatments: Surgical Embolectomy; Supportive Care
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck And Co.Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pulmonary Embolism Market Characteristics

3. Pulmonary Embolism Market Trends And Strategies

4. Pulmonary Embolism Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Pulmonary Embolism Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pulmonary Embolism PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pulmonary Embolism Market Growth Rate Analysis
• 5.4. Global Pulmonary Embolism Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pulmonary Embolism Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pulmonary Embolism Total Addressable Market (TAM)

6. Pulmonary Embolism Market Segmentation

• 6.1. Global Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Mechanical Devices
• Other Treatments
• 6.2. Global Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chest X-Ray
• Electrocardiogram (ECG)
• Magnetic Resonance Imaging (MRI)
• Computed Tomography Scan
• Pulmonary Angiography
• Venography
• Venous Ultrasound
• D-Dimer Test
• Other Diagnosis
• 6.3. Global Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Shortness Of Breath
• Chest Pain
• Cough
• Irregular Heartbeat
• Dizziness
• Fever
• Cyanosis
• Other Symptoms
• 6.4. Global Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Pulmonary Embolism Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticoagulants
• Thrombolytics
• 6.7. Global Pulmonary Embolism Market, Sub-Segmentation Of Mechanical Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inferior Vena Cava (IVC) Filters
• Catheter-Assisted Thrombectomy
• 6.8. Global Pulmonary Embolism Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Embolectomy
• Supportive Care

7. Pulmonary Embolism Market Regional And Country Analysis

• 7.1. Global Pulmonary Embolism Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pulmonary Embolism Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pulmonary Embolism Market

• 8.1. Asia-Pacific Pulmonary Embolism Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pulmonary Embolism Market

• 9.1. China Pulmonary Embolism Market Overview
• 9.2. China Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pulmonary Embolism Market

• 10.1. India Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pulmonary Embolism Market

• 11.1. Japan Pulmonary Embolism Market Overview
• 11.2. Japan Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pulmonary Embolism Market

• 12.1. Australia Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pulmonary Embolism Market

• 13.1. Indonesia Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pulmonary Embolism Market

• 14.1. South Korea Pulmonary Embolism Market Overview
• 14.2. South Korea Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pulmonary Embolism Market

• 15.1. Western Europe Pulmonary Embolism Market Overview
• 15.2. Western Europe Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pulmonary Embolism Market

• 16.1. UK Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pulmonary Embolism Market

• 17.1. Germany Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pulmonary Embolism Market

• 18.1. France Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pulmonary Embolism Market

• 19.1. Italy Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pulmonary Embolism Market

• 20.1. Spain Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pulmonary Embolism Market

• 21.1. Eastern Europe Pulmonary Embolism Market Overview
• 21.2. Eastern Europe Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pulmonary Embolism Market

• 22.1. Russia Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pulmonary Embolism Market

• 23.1. North America Pulmonary Embolism Market Overview
• 23.2. North America Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pulmonary Embolism Market

• 24.1. USA Pulmonary Embolism Market Overview
• 24.2. USA Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pulmonary Embolism Market

• 25.1. Canada Pulmonary Embolism Market Overview
• 25.2. Canada Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pulmonary Embolism Market

• 26.1. South America Pulmonary Embolism Market Overview
• 26.2. South America Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pulmonary Embolism Market

• 27.1. Brazil Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pulmonary Embolism Market

• 28.1. Middle East Pulmonary Embolism Market Overview
• 28.2. Middle East Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pulmonary Embolism Market

• 29.1. Africa Pulmonary Embolism Market Overview
• 29.2. Africa Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pulmonary Embolism Market Competitive Landscape And Company Profiles

• 30.1. Pulmonary Embolism Market Competitive Landscape
• 30.2. Pulmonary Embolism Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck And Co.Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Pulmonary Embolism Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Bristol Myers Squibb Company
• 31.4. GSK plc
• 31.5. Abbott Laboratories
• 31.6. AstraZeneca plc
• 31.7. Medtronic plc
• 31.8. Eli Lilly and Company
• 31.9. Gilead Sciences Inc.
• 31.10. Baxter International Inc.
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Regeneron Pharmaceuticals Inc.
• 31.13. Mylan N.V.
• 31.14. Daiichi Sankyo Co. Ltd.
• 31.15. Boehringer Ingelheim International GmbH

32. Global Pulmonary Embolism Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Embolism Market

34. Recent Developments In The Pulmonary Embolism Market

35. Pulmonary Embolism Market High Potential Countries, Segments and Strategies

• 35.1 Pulmonary Embolism Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pulmonary Embolism Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pulmonary Embolism Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer